Compare iShares MSCI Canada (TSX) (EWC) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Mesoblast Limited — how do they compare? iShares MSCI Canada (TSX) trades at $59.34, while Mesoblast Limited trades at $18.69 (market cap $2.31B). The key difference: iShares MSCI Canada (TSX) is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| EWC | MESO | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $59.49 | $20.96 |
52-Week Low | $45.86 | $11.35 |
Market Cap | — | $2.31B |
Enterprise Value | — | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $59.38, up 0.34% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows strong momentum near key resistance at $60, supported by positive Canadian economic news including trade surpluses and nuclear energy expansion plans. A dividend of $0.28 is scheduled for June 2026, adding income appeal.
Outlook remains positive due to Canada's economic recovery and commodity strength, though risks include US trade policy uncertainty and high RSI levels suggesting near-term consolidation. Institutional sentiment is bullish, with technical support at $59 providing a floor for potential gains.
Mesoblast (MESO) trades at $19.12, up 14.22% with strong bullish technical signals from moving averages. The biotech company shows promising commercial progress with FDA-approved Ryoncil generating $115M annual revenue, though fundamentals reveal significant losses with a -144.33% net income margin and negative EBITDA of -$80.06M. Recent milestones include achieving Phase 3 trial targets for chronic low back pain and receiving a BLA filing number for heart failure treatment.
Investment outlook balances high growth potential from Mesoblast's cellular medicine platform against substantial financial losses and valuation concerns. The company's transition to commercial operations and pipeline advancements present opportunities, while persistent cash burn and negative profitability represent key risks requiring careful monitoring of upcoming clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
